


PHARMACEUTICAL 2022



Organon & Co. Rank 21 of 475







PHARMACEUTICAL 2022



Organon & Co. Rank 21 of 475



The relative strengths and weaknesses of Organon & Co. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organon & Co. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 435% points. The greatest weakness of Organon & Co. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 496% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	3,760,000
Cost of Goods Sold	2,382,000
Intangible Assets	5,254,000
Liabilities, Current	2,597,000
Liabilities, Non-Current	0
Other Assets	694,000
Other Compr. Net Income	98,000
Other Expenses	460,000
Other Liabilities	0
Other Net Income	0
Property and Equipment	973,000
Research and Development	443,000
Revenues	6,304,000
Selling, General and Administrative Expense	1,668,000

Output Variable	Value in 1000 USD
Assets	10,681,000
Liabilities	2,597,000
Expenses	4,953,000
Stockholders Equity	8,084,000
Net Income	1,351,000
Comprehensive Net Income	1,400,000
Economic Capital Ratio	220%